9 September 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today published advice accepting five new medicines.

Tisagenlecleucel (Kymriah) was accepted for the treatment of adult patients with diffuse B cell lymphoma who have relapsed or not responded after two previous lines of treatment.

Pembrolizumab (Keytruda) for metastatic squamous non-small cell lung cancer was also accepted following consideration through the PACE process.

Read SMC press release